Document Type

Article

Publication Date

12-2018

Keywords

early detection, lung cancer screening, National Lung Screening Trial, quantitative imaging, Radiomics

Digital Object Identifier (DOI)

https://doi.org/10.1002/cam4.1852

Abstract

Background: Current guidelines for lung cancer screening increased a positive scan threshold to a 6 mm longest diameter. We extracted radiomic features from baseline and follow‐up screens and performed size‐specific analyses to predict lung cancer incidence using three nodule size classes (<6 mm [small], 6‐16 mm [intermediate], and ≥16 mm [large]).

Methods: We extracted 219 features from baseline (T0) nodules and 219 delta features which are the change from T0 to first follow‐up (T1). Nodules were identified for 160 incidence cases diagnosed with lung cancer at T1 or second follow‐up screen (T2) and for 307 nodule‐positive controls that had three consecutive positive screens not diagnosed as lung cancer. The cases and controls were split into training and test cohorts; classifier models were used to identify the most predictive features.

Results: The final models revealed modest improvements for baseline and delta features when compared to only baseline features. The AUROCs for small‐ and intermediate‐sized nodules were 0.83 (95% CI 0.76‐0.90) and 0.76 (95% CI 0.71‐0.81) for baseline‐only radiomic features, respectively, and 0.84 (95% CI 0.77‐0.90) and 0.84 (95% CI 0.80‐0.88) for baseline and delta features, respectively. When intermediate and large nodules were combined, the AUROC for baseline‐only features was 0.80 (95% CI 0.76‐0.84) compared with 0.86 (95% CI 0.83‐0.89) for baseline and delta features.

Conclusions: We found modest improvements in predicting lung cancer incidence by combining baseline and delta radiomics. Radiomics could be used to improve current size‐based screening guidelines.

Rights Information

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Was this content written or created while at USF?

Yes

Citation / Publisher Attribution

Cancer Medicine, v. 7, issue 12, p. 6340-6356

Share

COinS